Dominik Humer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dominik Humer has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Gottfried Baier
Institute for Cell Genetics, Medical University of Innsbruck, 6020 Innsbruck, Austria
5 shared publications - Jiří Koutník
Institute for Cell Genetics, Medical University of Innsbruck, 6020 Innsbruck, Austria
3 shared publications - Victoria Klepsch
Institute for Cell Genetics, Medical University of Innsbruck, 6020 Innsbruck, Austria
3 shared publications - Daniel Schreiber
Institute for Cell Genetics, Medical University of Innsbruck, 6020 Innsbruck, Austria
2 shared publications Isabel Hölzl
2 shared publicationsKerstin Siegmund
2 shared publications
Latest Publications
- Open Access
- 27 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
NR2F6 deletion revives CAR-T cell function and induces antigen-agnostic immune memory in solid tumors
CAR-T cell therapy is effective in hematologic malignancies but remains challenging in solid tumors owing to antigen heterogeneity and tumor microenvironment-induced exhaustion. Here, gene editing of the nuclear receptor NR2F6 restores CAR-T cell functionality, sustaining a TCF1⁺ progenitor-exhausted phenotype, enhancing metabolic fitness, and preserving cytotoxic potency under chronic antigen exposure. In immunocompetent models, Nr2f6-deficient CAR-T cells suppress solid tumor growth and induce robust, polyclonal host antitumor responses that persist after CAR-T clearance, as demonstrated by tumor re-challenge protection. Although infused CAR-T cells disappear within 2 weeks, durable tumor control coincides with epitope spreading and secondary immune responses, likely via dendritic cell reactivation. Protection against antigen-negative tumors and transferable immunity reveal a dual mode of direct cytotoxicity followed by durable immune reprogramming. This broadened host immunity may offset immune escape driven by antigen heterogeneity or loss, establishing NR2F6 inhibition as a promising CAR-T engineering strategy for durable, antigen-agnostic solid-tumor immunotherapy.
- 27 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessNR2F6 deletion revives CAR-T cell function and induces antigen-agnostic immune memory in solid tumors
CAR-T cell therapy is effective in hematologic malignancies but remains challenging in solid tumors owing to antigen heterogeneity and tumor microenvironment-induced exhaustion. Here, gene editing of the nuclear receptor NR2F6 restores CAR-T cell functionality, sustaining a TCF1⁺ progenitor-exhausted phenotype, enhancing metabolic fitness, and preserving cytotoxic potency under chronic antigen exposure. In immunocompetent models, Nr2f6-deficient CAR-T cells suppress solid tumor growth and induce robust, polyclonal host antitumor responses that persist after CAR-T clearance, as demonstrated by tumor re-challenge protection. Although infused CAR-T cells disappear within 2 weeks, durable tumor control coincides with epitope spreading and secondary immune responses, likely via dendritic cell reactivation. Protection against antigen-negative tumors and transferable immunity reveal a dual mode of direct cytotoxicity followed by durable immune reprogramming. This broadened host immunity may offset immune escape driven by antigen heterogeneity or loss, establishing NR2F6 inhibition as a promising CAR-T engineering strategy for durable, antigen-agnostic solid-tumor immunotherapy.
- Open Access
- 22 October 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (11) , 2582
Inhibition of PKCθ Abrogates CD8+ T Cell-Mediated Neurotoxicity in Murine Cerebral Malaria
Background: Cerebral malaria (CM) is a severe and often fatal complication of Plasmodium falciparum infection that causes devastating brain injury largely through immune-mediated mechanisms. Pathogenic brain-infiltrating CD8+ T cells are key drivers of CM pathology, yet the intracellular signals enabling their harmful autoimmune-like activity remain poorly defined. Here, we identify protein kinase C θ (PKCθ), a central antigen receptor-signalling mediator, as a critical contributor to experimental cerebral malaria (ECM). Methods/Results: Using a PKCθ null allele mouse strain on a C57BL/6N background, we demonstrate that PKCθ deficiency significantly improves survival in Plasmodium berghei ANKA (PbA)-infected mice without altering parasite burdens in the blood or brain. Mechanistically, loss of PKCθ skews T cell differentiation towards central memory (Tcm) rather than effector memory (Tem) phenotypes, thereby reducing effector differentiation and sequestration of CD8+ T cells in the cerebral microvasculature. This prevents extensive neurovascular damage, preserves neural tissue integrity, and alleviates neurological signs and symptoms. Our findings provide genetic evidence that PKCθ drives CD8+ T cell-mediated brain injury in ECM. Conclusions: These results underscore the potential for repurposing clinically PKCθ inhibitors as host-targeted interventions to protect against cerebral injury and improve outcomes in patients with CM.
- 22 October 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (11) , 2582
Open AccessInhibition of PKCθ Abrogates CD8+ T Cell-Mediated Neurotoxicity in Murine Cerebral Malaria
Background: Cerebral malaria (CM) is a severe and often fatal complication of Plasmodium falciparum infection that causes devastating brain injury largely through immune-mediated mechanisms. Pathogenic brain-infiltrating CD8+ T cells are key drivers of CM pathology, yet the intracellular signals enabling their harmful autoimmune-like activity remain poorly defined. Here, we identify protein kinase C θ (PKCθ), a central antigen receptor-signalling mediator, as a critical contributor to experimental cerebral malaria (ECM). Methods/Results: Using a PKCθ null allele mouse strain on a C57BL/6N background, we demonstrate that PKCθ deficiency significantly improves survival in Plasmodium berghei ANKA (PbA)-infected mice without altering parasite burdens in the blood or brain. Mechanistically, loss of PKCθ skews T cell differentiation towards central memory (Tcm) rather than effector memory (Tem) phenotypes, thereby reducing effector differentiation and sequestration of CD8+ T cells in the cerebral microvasculature. This prevents extensive neurovascular damage, preserves neural tissue integrity, and alleviates neurological signs and symptoms. Our findings provide genetic evidence that PKCθ drives CD8+ T cell-mediated brain injury in ECM. Conclusions: These results underscore the potential for repurposing clinically PKCθ inhibitors as host-targeted interventions to protect against cerebral injury and improve outcomes in patients with CM.
- Open Access
- 24 June 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (6) , e011056
Potentiation of cancer immunogenicity by targeting PARP
A team of scientists led by Quigley Goa demonstrates that Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) can induce tumor cell death in a manner that allows immune cells to better recognize and attack the tumor. Specifically, PARPi are approved for the treatment of tumors with homologous recombination repair defects. Due to their pre-existing DNA repair defects, PAPRi appear to be a pharmacological tool to induce immunogenic cell death (ICD). Remarkably, therefore, both increased tumor neoantigen generation and reprogramming of the tumor immune microenvironment to an immunostimulatory state antagonize impending immunosuppression and consequently promote enhanced antitumor immunity. This finding strongly supports PARPi targeting as a promising approach to alleviate intratumoral effector T cell immune dysfunction, particularly in the context of immunotherapy resistance. In conclusion, this well-defined relationship between PARPi-based chemotherapy and ICD of tumor cells may offer substantial potential as a valuable sensitizer for future combinatorial cancer immunotherapy, which together with immune checkpoint therapy, but potentially also with others including cancer vaccines, is likely to be more effective against defined solid tumors and better promote host-protective cancer immune control (see related article by Xia et al, 2024).
- 24 June 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (6) , e011056
Open AccessPotentiation of cancer immunogenicity by targeting PARP
A team of scientists led by Quigley Goa demonstrates that Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) can induce tumor cell death in a manner that allows immune cells to better recognize and attack the tumor. Specifically, PARPi are approved for the treatment of tumors with homologous recombination repair defects. Due to their pre-existing DNA repair defects, PAPRi appear to be a pharmacological tool to induce immunogenic cell death (ICD). Remarkably, therefore, both increased tumor neoantigen generation and reprogramming of the tumor immune microenvironment to an immunostimulatory state antagonize impending immunosuppression and consequently promote enhanced antitumor immunity. This finding strongly supports PARPi targeting as a promising approach to alleviate intratumoral effector T cell immune dysfunction, particularly in the context of immunotherapy resistance. In conclusion, this well-defined relationship between PARPi-based chemotherapy and ICD of tumor cells may offer substantial potential as a valuable sensitizer for future combinatorial cancer immunotherapy, which together with immune checkpoint therapy, but potentially also with others including cancer vaccines, is likely to be more effective against defined solid tumors and better promote host-protective cancer immune control (see related article by Xia et al, 2024).
- Open Access
- 26 May 2024
- Published by Wiley in Immunology
- Vol. 173 (1) , 125-140
T cell‐intrinsic PKD3 fine‐tunes differentiation into CD8+ central memory T cells and CD8 single positive thymocyte development
Members of the Protein kinases D (PKD) family are described as regulators of T cell responses. From the two T cell-expressed isoforms PKD2 and PKD3, so far mainly the former was thoroughly investigated and is well understood. Recently, we have investigated also PKD3 using conventional as well as conditional T cell-specific knockout models. These studies suggested PKD3 to be a T cell-extrinsic regulator of the cells' fate. However, these former model systems did not take into account possible redundancies with the highly homologous PKD2. To overcome this issue and thus properly unravel PKD3's T cell-intrinsic functions, here we additionally used a mouse model overexpressing a constitutively active isoform of PKD3 specifically in the T cell compartment. These transgenic mice showed a slightly higher proportion of central memory T cells in secondary lymphoid organs and blood. This effect could not be explained via differences upon polyclonal stimulation in vitro, however, may be connected to the observed developmental aberrances in the CD8 single positive compartment during thymic development. Lastly, the observed alterations in the CD8(+) T cell compartment did not impact proper immune response upon immunization with ovalbumin or in a subcutaneous tumour model suggesting only a small to absent biological relevance. Taking together the knowledge of all our published studies on PKD3 in the T cell compartment, we now conclude that T cell-intrinsic PKD3 is a fine-tuner of central memory T cell as well as CD8 single positive thymocyte development.
- 26 May 2024
- Published by Wiley in Immunology
- Vol. 173 (1) , 125-140
Open AccessT cell‐intrinsic PKD3 fine‐tunes differentiation into CD8+ central memory T cells and CD8 single positive thymocyte development
Members of the Protein kinases D (PKD) family are described as regulators of T cell responses. From the two T cell-expressed isoforms PKD2 and PKD3, so far mainly the former was thoroughly investigated and is well understood. Recently, we have investigated also PKD3 using conventional as well as conditional T cell-specific knockout models. These studies suggested PKD3 to be a T cell-extrinsic regulator of the cells' fate. However, these former model systems did not take into account possible redundancies with the highly homologous PKD2. To overcome this issue and thus properly unravel PKD3's T cell-intrinsic functions, here we additionally used a mouse model overexpressing a constitutively active isoform of PKD3 specifically in the T cell compartment. These transgenic mice showed a slightly higher proportion of central memory T cells in secondary lymphoid organs and blood. This effect could not be explained via differences upon polyclonal stimulation in vitro, however, may be connected to the observed developmental aberrances in the CD8 single positive compartment during thymic development. Lastly, the observed alterations in the CD8(+) T cell compartment did not impact proper immune response upon immunization with ovalbumin or in a subcutaneous tumour model suggesting only a small to absent biological relevance. Taking together the knowledge of all our published studies on PKD3 in the T cell compartment, we now conclude that T cell-intrinsic PKD3 is a fine-tuner of central memory T cell as well as CD8 single positive thymocyte development.